Investor Relations

AVEO Oncology is a biopharmaceutical company committed to developing targeted therapies through biomarker-driven insights to provide substantial improvements in patient outcomes where significant unmet medical needs exist. AVEO’s proprietary Human Response Platform™ has delivered unique insights into cancer and related disease biology that are being leveraged in the clinical development of its therapeutic candidates.

NASDAQ | AVEO (Common Stock)
$1.41 + 0.03
Stock chart for: AVEO.O.  Currently trading at $1.41 with a 52 week high of $3.50 and a 52 week low of $0.61.
07/31/15 4:00 p.m. ET
Data Provided by Thomson Reuters

Press Releases

AVEO Oncology Announces Additional Biomarker Analyses from BATON-CRC Tivozanib Study to be Presented at the ESMO 17th World Congress on Gastrointestinal CancerRead More
AVEO Announces FDA Update for Tivozanib in Colorectal CancerRead More
AVEO Announces Receipt of European Regulatory Guidance Regarding Potential Marketing Authorization Application for TivozanibRead More